Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Activist investor Ananym Capital Management is urging healthcare products distributor Henry Schein to refresh its board, cut costs, tackle succession planning and consider selling its medical ...

Henry Schein (NASDAQ:HSIC) rose 7.4% amid a report that an activist investor has taken a stake and is pushing for the dental ...

Activist Ananym Capital Management is urging Henry Schein (HSIC) to refresh its board, cut costs, tackle succession planning and consider selling its medical distribution business, Svea Herbst-Bayliss ...

Gulf International Bank UK Ltd trimmed its position in Henry Schein, Inc. (NASDAQ:HSIC – Free Report) by 3.1% in the 3rd ...

Q3 2024 Earnings Call Transcript November 5, 2024 Henry Schein, Inc. beats earnings expectations. Reported EPS is $1.22, ...

Analyst Erin Wright of Morgan Stanley maintained a Sell rating on Henry Schein (HSIC – Research Report), retaining the price target of ...

Henry Schein Trading Up 0.2 % NASDAQ:HSIC opened at $70.37 on Friday. The stock has a market cap of $8.92 billion, a PE ratio of 26.06, a price-to-earnings-growth ratio of 2.02 and a beta of 0.87 ...

The 26-year-old passed the NFL’s five-step return to participation protocol, was cleared to play by an independent neurological consultant, and gathered feedback from some of the top medical ...

Henry Schein is a Fortune 500 company and one of the global leaders in its industry, providing healthcare solutions, as well as the distribution of medical, dental, and veterinary supplies.

“We are honored to partner with Halub Medical, a top healthcare provider in the Middle East,” said Shu Li, PhD, Founder and Executive Chairman of the Board of Directors of Helio Genomics.